

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 December 2000 (14.12.2000)

PCT

(10) International Publication Number
WO 00/75108 A1

(51) International Patent Classification⁷: C07D 211/28,
401/12, 409/12, A61K 31/445, 31/4535, A61P 19/02

(21) International Application Number: PCT/GB00/02085

(22) International Filing Date: 31 May 2000 (31.05.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
99401350.6 4 June 1999 (04.06.1999) EP

(71) Applicants (for all designated States except US): AS-
TRAZENECA UK LIMITED [GB/GB]; 15 Stanhope
Gate, London W1Y 6LN (GB). ZENECA-PHARMA
S.A. [FR/FR]; 'Le Galien', 1, rue des Chauffours, Boîte
postale 127, F-95022 Cergy Cedex (FR).

(72) Inventor; and

(75) Inventor/Applicant (for US only): TUCKER, Howard
[GB/GB]; Alderley Park, Macclesfield, Cheshire SK10
4TG (GB).

(74) Agent: PHILIPS, Neil, Godfrey, Alasdair; AstraZeneca,
P.O. Box 272, Mereside, Alderley Park, Macclesfield,
Cheshire SK10 4TG (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: INHIBITORS OF METALLOPROTEINASES



(57) Abstract: Arylpiperazines of formula (I) having a heterocyclylalkyl substituent at R2, useful as metalloproteinase inhibitors, especially useful as MMP13 inhibitors.

WO 00/75108 A1

INHIBITORS OF METALLOPROTEINASES

The present invention relates to compounds useful in the inhibition of metalloproteinases and in particular to pharmaceutical compositions comprising these, as well as their use.

The compounds of this invention are inhibitors of one or more metalloproteinase enzymes. Metalloproteinases are a superfamily of proteinases (enzymes) whose numbers in recent years have increased dramatically. Based on structural and functional considerations these enzymes have been classified into families and subfamilies as described in N. M Hooper (1994) FEBS Letters 354:1-6. Examples of metalloproteinases include the matrix metalloproteinases (MMP) such as the collagenases (MMP1, MMP8, MMP13), the gelatinases (MMP2, MMP9), the stromelysins (MMP3, MMP10, MMP11), matrilysin (MMP7), metalloelastase (MMP12), enamelysin (MMP19), the MT-MMPs (MMP14, MMP15, MMP16, MMP17); the reprolysin or adamalysin or MDC family which includes the secretases and sheddases such as TNF converting enzymes (ADAM10 and TACE); the astacin family which include enzymes such as procollagen processing proteinase (PCP); and other metalloproteinases such as aggrecanase, the endothelin converting enzyme family and the angiotensin converting enzyme family.

Metalloproteinases are believed to be important in a plethora of physiological disease processes that involve tissue remodelling such as embryonic development, bone formation and uterine remodelling during menstruation. This is based on the ability of the metalloproteinases to cleave a broad range of matrix substrates such as collagen, proteoglycan and fibronectin. Metalloproteinases are also believed to be important in the processing, or secretion, of biological important cell mediators, such as tumour necrosis factor (TNF); and the post translational proteolysis processing, or shedding, of biologically important membrane proteins, such as the low affinity IgE receptor CD23 (for a more complete list see N. M. Hooper *et al.*, (1997) Biochem J. 321:265-279).

Metalloproteinases have been associated with many disease conditions. Inhibition of the activity of one or more metalloproteinases may well be of benefit in these disease conditions, for example: various inflammatory and allergic diseases such as, inflammation of the joint (especially rheumatoid arthritis, osteoarthritis and gout), inflammation of the gastrointestinal tract (especially inflammatory bowel disease, ulcerative colitis and gastritis), inflammation of the skin (especially psoriasis, eczema, dermatitis); in tumour metastasis or

invasion; in disease associated with uncontrolled degradation of the extracellular matrix such as osteoarthritis; in bone resorptive disease (such as osteoporosis and Paget's disease)); in diseases associated with aberrant angiogenesis; the enhanced collagen remodelling associated with diabetes, periodontal disease (such as gingivitis), corneal ulceration, ulceration of the skin, post-operative conditions (such as colonic anastomosis) and dermal wound healing; demyelinating diseases of the central and peripheral nervous systems (such as multiple sclerosis); Alzheimer's disease; and extracellular matrix remodelling observed in cardiovascular diseases such as restenosis and atherosclerosis.

A number of metalloproteinase inhibitors are known; different classes of compounds may have different degrees of potency and selectivity for inhibiting various metalloproteinases. We have discovered a new class of compounds that are inhibitors of metalloproteinases and are of particular interest in inhibiting MMP-13. The compounds of this invention have beneficial potency and/or pharmacokinetic properties.

MMP13, or collagenase 3, was initially cloned from a cDNA library derived from a breast tumour [J. M. P. Freije *et al.* (1994) *Journal of Biological Chemistry* 269(24):16766-16773]. PCR-RNA analysis of RNAs from a wide range of tissues indicated that MMP13 expression was limited to breast carcinomas as it was not found in breast fibroadenomas, normal or resting mammary gland, placenta, liver, ovary, uterus, prostate or parotid gland or in breast cancer cell lines (T47-D, MCF-7 and ZR75-1). Subsequent to this observation MMP13 has been detected in transformed epidermal keratinocytes [N. Johansson *et al.*, (1997) *Cell Growth Differ.* 8(2):243-250], squamous cell carcinomas [N. Johansson *et al.*, (1997) *Am. J. Pathol.* 151(2):499-508] and epidermal tumours [K. Airola *et al.*, (1997) *J. Invest. Dermatol.* 109(2):225-231]. These results are suggestive that MMP13 is secreted by transformed epithelial cells and may be involved in the extracellular matrix degradation and cell-matrix interaction associated with metastasis especially as observed in invasive breast cancer lesions and in malignant epithelia growth in skin carcinogenesis.

Recent published data implies that MMP13 plays a role in the turnover of other connective tissues. For instance, consistent with MMP13's substrate specificity and preferential to degrade type II collagen [P. G. Mitchell *et al.*, (1996) *J. Clin. Invest.* 97(3):761-768; V. Knauper *et al.*, (1996) *The Biochemical Journal* 271:1544-1550], MMP13 has been hypothesised to serve a role during primary ossification and skeletal remodelling [M. Stahle-Backdahl *et al.*, (1997) *Lab. Invest.* 76(5):717-728; N. Johansson *et al.*, (1997) *Dev. Dyn.* 208(3):387-397], in destructive joint diseases such as rheumatoid and osteo-arthritis [D.

Wernicke *et al.*, (1996) *J. Rheumatol.* 23:590-595; P. G. Mitchell *et al.*, (1996) *J. Clin. Invest.* 97(3):761-768; O. Lindy *et al.*, (1997) *Arthritis Rheum* 40(8):1391-1399]; and during the aseptic loosening of hip replacements [S. Imai *et al.*, (1998) *J. Bone Joint Surg. Br.* 80(4):701-710]. MMP13 has also been implicated in chronic adult periodontitis as it has been localised
5 to the epithelium of chronically inflamed mucosa human gingival tissue [V. J. Uitto *et al.*, (1998) *Am. J. Pathol* 152(6):1489-1499] and in remodelling of the collagenous matrix in chronic wounds [M. Vaalamo *et al.*, (1997) *J. Invest. Dermatol.* 109(1):96-101].


MMP9 (Gelatinase B; 92kDa TypeIV Collagenase; 92kDa Gelatinase) is a secreted protein which was first purified, then cloned and sequenced, in 1989 (S.M. Wilhelm *et al*
10 (1989) *J. Biol Chem.* 264 (29) : 17213-17221. Published erratum in *J. Biol Chem.* (1990) 265 (36) : 22570.). A recent review of MMP9 provides an excellent source for detailed information and references on this protease : T.H. Vu & Z. Werb (1998) (In : *Matrix Metalloproteinases*. 1998. Edited by W.C. Parks & R.P. Mecham. pp115 - 148. Academic Press. ISBN 0-12-545090-7). The following points are drawn from that review by T.H. Vu &
15 Z. Werb (1998).

The expression of MMP9 is restricted normally to a few cell types, including trophoblasts, osteoclasts, neutrophils and macrophages. However, its expression can be induced in these same cells and in other cell types by several mediators, including exposure of the cells to growth factors or cytokines. These are the same mediators often implicated in
20 initiating an inflammatory response. As with other secreted MMPs, MMP9 is released as an inactive pro-enzyme which is subsequently cleaved to form the enzymatically active enzyme. The proteases required for this activation *in vivo* are not known. The balance of active MMP9 versus inactive enzyme is further regulated *in vivo* by interaction with TIMP-1 (Tissue Inhibitor of Metalloproteinases -1), a naturally-occurring protein. TIMP-1 binds to the C-
25 terminal region of MMP9, leading to inhibition of the catalytic domain of MMP9. The balance of induced expression of ProMMP9, cleavage of Pro- to active MMP9 and the presence of TIMP-1 combine to determine the amount of catalytically active MMP9 which is present at a local site. Proteolytically active MMP9 attacks substrates which include gelatin, elastin, and native Type IV and Type V collagens; it has no activity against native Type I
30 collagen, proteoglycans or laminins.

There has been a growing body of data implicating roles for MMP9 in various physiological and pathological processes. Physiological roles include the invasion of embryonic trophoblasts through the uterine epithelium in the early stages of embryonic

- implantation; some role in the growth and development of bones; and migration of inflammatory cells from the vasculature into tissues. Increased MMP9 expression has been observed in certain pathological conditions, thereby implicating MMP9 in disease processes such as arthritis, tumour metastasis, Alzheimer's, Multiple Sclerosis, and plaque rupture in atherosclerosis leading to acute coronary conditions such as Myocardial Infarction.

In a first aspect of the invention we provide compounds of the formula I



- wherein ring B is a monocyclic or bicyclic alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl ring comprising up to 12 ring atoms and containing one or more heteroatoms independently chosen from N, O, and S; alternatively ring B may be biphenyl; ring B may optionally be linked to ring A by a C1-4 alkyl or a C1-4 alkoxy chain linking the 2-position of ring B with a carbon atom alpha to X2;
- each R3 is independently selected from hydrogen, halogen, NO₂, COOR wherein R is hydrogen or C1-6alkyl, CN, CF₃, C1-6 alkyl, -S-C1-6 alkyl, -SO-C1-6 alkyl, -SO₂-C1-6 alkyl, C1-6 alkoxy and up to C10 aryloxy, n is 1,2 or 3;

- P is -(CH₂)_n- wherein n = 0, 1, 2, or P is an alkene or alkyne chain of up to six carbon atoms; where X₂ is C, P may be -Het-, -(CH[R₆])_n-Het-, -Het-(CH[R₆])_n- or -Het-(CH[R₆])_n-Het-, wherein Het is selected from -CO-, -S-, -SO-, -SO₂-, -NR₆-, or -O- wherein n is 1 or 2, or P may be selected from -CO-N(R₆)-, -N(R₆)-CO-, -SO₂-N(R₆)- and -N(R₆)-SO₂-, and R₆ is hydrogen, C1-6 alkyl, up to C10 aralkyl or up to C₉ heteroalkyl;

- Ring A is a 5-7 membered aliphatic ring and may optionally be mono- or di-substituted by optionally substituted C1-6 alkyl or C1-6 alkoxy, each substituent being independently selected from halogen, C1-6 alkyl or an oxo group;

X₁ and X₂ are independently selected from N and C, where a ring substituent on ring A is an oxo group this is preferably adjacent a ring nitrogen atom;

Y is selected from -SO₂- and -CO-;

Z is -CONHOH, Y is -CO- and Q is selected from -C(R6)(R7)-, -C(R6)(R7)-CH2-, -N(R6)-, and -N(R6)-CH2- wherein R6 is as defined above, and solely in relation to Q as here defined, R6 may also represent up to C10 aryl and up to C9 heteroaryl, and R7 is H, C1-6 alkyl, or together with R6 forms a carbocyclic or heterocyclic spiro 5, 6 or 7 membered ring,
5 the latter containing at least one heteroatom selected from N, O, and S;

Z is -CONHOH, Y is -SO2- and Q is selected from -C(R6)(R7)-, and —C(R6)(R7)-CH2-;

or Z is -N(OH)CHO and Q is selected from -CH(R6)-, -CH(R6)-CH2-, and -N(R6)-CH2-;

10 R1 is H, or C1-6 alkyl;

Z is selected from -COOH, -CONHOH, -N(OH)CHO and N(OH)COR wherein R is C1-6alkyl, up to C10 aryl and up to C9 aralkyl

and R2 is a heterocyclalkyl ring having 5-7 ring atoms and comprising one or two ring heteroatoms independently selected from oxygen, nitrogen and sulphur, the ring being
15 optionally substituted by (i) Y-R9 wherein R9 is C1-6 alkyl, up to C10 aryl, up to C12 aralkyl or up to C12 heteroaryl(hetero)alkyl, or (ii) Y-T-R9 wherein Y and R9 are as previously defined and T is oxygen or N-R8 wherein R8 is hydrogen or C1-6alkyl, the heteroatom(s) being independently selected from oxygen, nitrogen and sulphur; R9 and R8 independently being optionally substituted by one or two groups selected from halogen, NO2, CN, CF3, C1-
20 6 alkyl, -S-C1-6 alkyl, -SO-C1-6 alkyl, -SO2-C1-6 alkyl and C1-6 alkoxy.

Any alkyl groups outlined above may be straight chain or branched.

Convenient values for the above groups include the following:

ring A = a 5-6 membered aliphatic ring, such as a piperazine or piperidine ring, and may optionally be mono- or di-substituted by optionally substituted C1-6 alkyl or C1-6
25 alkoxy, each substituent being independently selected from halogen, C1-6 alkyl or an oxo group;

R3 = hydrogen, halogen, NO2, CF3, C1-4 alkyl, and C1-4 alkoxy, n is 1 or 2, such as individually 4-fluoro, CF3, 4-chloro and 3,4-dichloro;

ring B = monocyclic or bicyclic cycloalkyl, aryl, aralkyl or heteroaryl having up to 10
30 ring atoms, especially monocyclic aryl, aralkyl or heteroaryl having up to 7 ring atoms, more especially monocyclic aryl or heteroaryl having up to 6 ring atoms, such as a phenyl or pyridyl ring;

P = -(CH₂)_n- wherein n is 0 or 1, or P is -NH-CO-

one or both of X₂ and X₁ = N

Y = -SO₂- or -CO-;

Q = -CH(R₆)-, -CH(R₆)-CH₂-, -N(R₆)-, and -N(R₆)-CH₂- wherein R₆ is hydrogen or

5 C1-6 alkyl; when Q = -N(R₆)-, or -N(R₆)-CH₂- then Y may also be -CS-; especially

Q = -CH(R₆)- wherein R₆ is hydrogen or C1-4 alkyl such as propyl or butyl, particularly propyl.; also where Q is linked to R₁ or R₂ to form a 5-7 alkyl or heteroalkyl ring such as a cyclohexyl ring;

R₁ = hydrogen, or C1-4 alkyl.

10 Z = -CONHOH- or -N(OH)CHO

and R₂ is a heterocyclalkyl ring having 5-7 ring atoms and comprising one or two ring heteroatoms independently selected from oxygen, nitrogen and sulphur, the ring being optionally substituted by (i) Y-R₉ wherein R₉ is C1-6 alkyl, up to C₁₀ aryl, up to C₁₂ aralkyl or up to C₁₂ heteroaryl(hetero)alkyl, or (ii) Y-T-R₉ wherein Y and R₉ are as previously
15 defined and T is oxygen or N-R₈ wherein R₈ is hydrogen or C1-6alkyl, the heteroatom(s) being independently selected from oxygen, nitrogen and sulphur; R₉ and R₈ independently being optionally substituted by one or two groups selected from halogen, NO₂, CN, CF₃, C1-6 alkyl, -S-C1-6 alkyl, -SO-C1-6 alkyl, -SO₂-C1-6 alkyl and C1-6 alkoxy.

Preferred values for the above groups include the following:

20 R₃ = hydrogen, chlorine, fluorine, NO₂, CF₃, methyl, ethyl, methoxy, ethoxy, particularly methoxy or fluorine;

ring B = phenyl, biphenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl, especially phenyl or pyridyl, more especially phenyl or 2-pyridyl;

ring A = piperazine;

25 P = a direct bond;

both X₂ and X₁ are N;

Y = -SO₂-;

Q = -CH₂-;

R₂ is a heterocyclalkyl ring having 5-7 ring atoms and comprising one or two ring
30 heteroatoms independently selected from oxygen, nitrogen and sulphur, the ring being optionally substituted by (i) Y-R₉ wherein Y is -SO₂- or -CO- and R₉ is C1-6 alkyl or alkylamino, up to C₁₀ aryl or arylamino, up to C₁₂ aralkyl or aralkylamino or up to C₁₂ heteroaryl(hetero)alkyl, R₉ independently being optionally substituted by one or two groups

selected from halogen, NO₂, CN, CF₃, C1-6 alkyl, -S-C1-6 alkyl, -SO-C1-6 alkyl, -SO₂-C1-6 alkyl and C1-6 alkoxy;

R1 is hydrogen;

Z is -N(OH)CHO;

5

More preferred values include:

R3 being methoxy, fluorine or 4-fluoro;

ring A is unsubstituted;

ring B is phenyl, pyridyl, or 2-pyridyl;

10

R2 is 3- or 4-piperidinyl, optionally N-substituted by Y-R9 wherein Y is -SO₂- or -CO- and R9 is C1-4 alkyl or alkylamino, C₆ aryl or arylamino, up to C₁₀ aralkyl or aralkylamino or up to C₁₀ heteroaryl(hetero)alkyl, R9 independently being optionally substituted by one or two groups selected from halogen, CF₃, and C1-4 alkyl;


15


Preferred combinations of Rings A and B include phenyl and piperazinyl; pyridyl and piperazinyl respectively.

Particular compounds include those where Ring A is unsubstituted.


Particular alicyclic, fused and heterocyclic rings for ring B include any one of

20





5 Particular rings for ring A include any one of



and its corresponding seven membered analogue(s).

It will be appreciated that the particular substituents and number of substituents on rings A and B are selected so as to avoid sterically undesirable combinations.

- 5 Where optically active centres exist in the compounds of formula I, we disclose all individual optically active forms and combinations of these as individual specific embodiments of the invention, as well as their corresponding racemates.

- 10 The above compounds are potent MMP13 inhibitors, they also have good aggrecanase activity. As previously outlined the compounds of the invention are metalloproteinase inhibitors, in particular they are inhibitors of MMP13. Each of the above indications for the compounds of the formula I represents an independent and particular embodiment of the invention. Whilst we do not wish to be bound by theoretical considerations, the compounds of the invention are believed to show selective inhibition for any one of the above indications relative to any MMP1 inhibitory activity, by way of non-limiting example they may show 100-
15 1000 fold selectivity over any MMP1 inhibitory activity.

- 20 The compounds of the invention may be provided as pharmaceutically acceptable salts. These include acid addition salts such as hydrochloride, hydrobromide, citrate and maleate salts and salts formed with phosphoric and sulphuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example sodium or potassium, an alkaline earth metal salt for example calcium or magnesium, or organic amine salt for example triethylamine.

- 25 They may also be provided as in vivo hydrolysable esters. These are pharmaceutically acceptable esters that hydrolyse in the human body to produce the parent compound. Such esters can be identified by administering, for example intravenously to a test animal, the compound under test and subsequently examining the test animal's body fluids. Suitable in vivo hydrolysable esters for carboxy include methoxymethyl and for hydroxy include acetyl.

In order to use a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof for the therapeutic treatment (including prophylactic treatment) of mammals including humans, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

5 Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable ester and pharmaceutically acceptable carrier.

The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, topical,
10 parenteral, buccal, nasal, vaginal or rectal administration or by inhalation. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or
15 oily solutions or suspensions or sterile emulsions.

In addition to the compounds of the present invention the pharmaceutical composition of this invention may also contain, or be co-administered (simultaneously or sequentially) with, one or more pharmacological agents of value in treating one or more disease conditions referred to hereinabove.

20 The pharmaceutical compositions of this invention will normally be administered to humans so that, for example, a daily dose of 0.5 to 75 mg/kg body weight (and preferably of 0.5 to 30 mg/kg body weight) is received. This daily dose may be given in divided doses as necessary, the precise amount of the compound received and the route of administration depending on the weight, age and sex of the patient being treated and on the particular disease
25 condition being treated according to principles known in the art.

Typically unit dosage forms will contain about 1 mg to 500 mg of a compound of this invention.

Therefore in a further aspect, the present invention provides a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof for use
30 in a method of therapeutic treatment of the human or animal body.



In yet a further aspect the present invention provides a method of treating a metalloproteinase mediated disease condition which comprises administering to a warm-

blooded animal a therapeutically effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.

In another aspect the present invention provides a process for preparing a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof

5 which process comprises

a) reacting a compound of the formula (II) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof with a compound of the formula (III)



10

wherein X_1^I represents X or a precursor of X (whether by modification or displacement) or an activated form of X suitable for reaction with Y_1 ;

Y_1 represents Y, a precursor of Y, or an activated form of Y suitable for reaction with X_1^I ;

15

by way of non-limiting example, when X is C then X_1 may be derivatised to include a precursor of Y for reaction with a compound of formula III wherein Y^I is a precursor of Y;


Z^I represents a protected form of Z, a precursor of Z (whether by modification or displacement of Z^I) or an activated form of Z;

or

20

b) reacting a compound of the formula (IV) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof with a compound of the formula (V).

- 12 -




wherein B¹ represents a suitable ring function or substituent group for reaction with Pⁱ; Z¹ is as hereinbefore defined; and

- 5 Pⁱ represents a suitably activated form of the linker P for reaction with B¹;

or

c) reacting a compound of the general formula (VIII)




- 10 wherein R2* is a precursor for R2 with appropriate reagent(s) in one or more steps to yield R2. The group Z is conveniently protected during such steps. By way of non-limiting example R2* is a piperidine or piperazine ring;



or

(d) reacting a compound of the formula IX with an appropriate compound of the formula R1-

- 15 CO-R2 to yield an alkene of the formula X, which is then converted to a compound of the formula XI wherein Z* is a hydroxylamine precursor of the group Z, and then converting Z* to the group Z, all as set out below:



A compound of the formula (II) is conveniently prepared by reacting a compound of
 5 the formula (VI) with a compound of the formula (VII)




wherein B^I represents a suitable ring function or substituent group, X₂^I represents X or a
 precursor of X (whether by modification or displacement) or an activated form of X suitable
 10 for reaction with B^I and wherein B^I and X₂^I when reacted together provide the linker P

between ring B and ring A in the compound of formula (II). By way of non-limiting example, when X_2 is N then ring A is suitably derivatised to introduce the linker P via B^1 , and when X_2 is C then both ring A and ring are suitably derivatised to provide the linker P by the reaction of B^1 and X_2^1 .

5

Convenient commercially available starting materials include



10 The compounds of the invention may be evaluated for example in any one of the following assays:

Isolated Enzyme Assays:

Matrix Metalloproteinase familv, including for example MMP13

Recombinant human proMMP13 may be expressed and purified as described by Knauper *et al.* [V. Knauper *et al.*, (1996) The Biochemical Journal 271:1544-1550 (1996)].
 15 The purified enzyme can be used to monitor inhibitors of activity as follows: purified proMMP13 is activated using 1mM amino phenyl mercuric acid (APMA), 20 hours at 21°C; the activated MMP13 (11.25ng per assay) is incubated for 4-5 hours at 35°C in assay buffer (0.1M Tris-HCl, pH 7.5 containing 0.1M NaCl, 20mM CaCl₂, 0.02 mM ZnCl and 0.05%
 20 (w/v) Brij 35 using the synthetic substrate 7-methoxycoumarin-4-yl)acetyl.Pro.Leu.Gly.Leu.N-3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl.Ala.Arg.NH₂ in the presence or absence of inhibitors. Activity is determined by measuring the fluorescence at λ_{ex} 328nm and λ_{em} 393nm. Percent inhibition is calculated as follows: % Inhibition is equal to the [Fluorescence_{plus inhibitor} - Fluorescence_{background}] divided by the [Fluorescence_{minus}
 25 inhibitor - Fluorescence_{background}].

A similar protocol can be used for other expressed and purified pro MMPs using substrates and buffers conditions optimal for the particular MMP, for instance as described in C. Graham Knight *et al.*, (1992) FEBS Lett. 296(3):263-266.

Adamalysin familv, including for example TNF convertase.

30 The ability of the compounds to inhibit proTNF α convertase enzyme may be assessed using a partially purified, isolated enzyme assay, the enzyme being obtained from the

membranes of THP-1 as described by K. M. Mohler *et al.*, (1994) Nature 370:218-220. The purified enzyme activity and inhibition thereof is determined by incubating the partially purified enzyme in the presence or absence of test compounds using the substrate 4',5'-Dimethoxy-fluoresceinyl Ser.Pro.Leu.Ala.Gln.Ala.Val.Arg.Ser.Ser.Ser.Arg.Cys(4-(3-succinimid-1-yl)-fluorescein)-NH₂ in assay buffer (50mM Tris HCl, pH 7.4 containing 0.1% (w/v) Triton X-100 and 2mM CaCl₂), at 26°C for 18 hours. The amount of inhibition is determined as for MMP13 except λ_{ex} 490nm and λ_{em} 530nm were used. The substrate was synthesised as follows. The peptidic part of the substrate was assembled on Fmoc-NH-Rink-MBHA-polystyrene resin either manually or on an automated peptide synthesiser by standard methods involving the use of Fmoc-amino acids and O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) as coupling agent with at least a 4- or 5-fold excess of Fmoc-amino acid and HBTU. Ser¹ and Pro² were double-coupled. The following side chain protection strategy was employed; Ser¹(Bu^t), Gln⁵(Trityl), Arg^{8,12}(Pmc or Pbf), Ser^{9,10,11}(Trityl), Cys¹³(Trityl). Following assembly, the N-terminal Fmoc-protecting group was removed by treating the Fmoc-peptidyl-resin with in DMF. The amino-peptidyl-resin so obtained was acylated by treatment for 1.5-2hr at 70°C with 1.5-2 equivalents of 4',5'-dimethoxy-fluorescein-4(5)-carboxylic acid [Khanna & Ullman, (1980) Anal Biochem. 108:156-161) which had been preactivated with diisopropylcarbodiimide and 1-hydroxybenzotriazole in DMF]. The dimethoxyfluoresceinyl-peptide was then simultaneously deprotected and cleaved from the resin by treatment with trifluoroacetic acid containing 5% each of water and triethylsilane. The dimethoxyfluoresceinyl-peptide was isolated by evaporation, trituration with diethyl ether and filtration. The isolated peptide was reacted with 4-(N-maleimido)-fluorescein in DMF containing diisopropylethylamine, the product purified by RP-HPLC and finally isolated by freeze-drying from aqueous acetic acid. The product was characterised by MALDI-TOF MS and amino acid analysis.

Natural Substrates

The activity of the compounds of the invention as inhibitors of aggrecan degradation may be assayed using methods for example based on the disclosure of E. C. Arner *et al.*, (1998) Osteoarthritis and Cartilage 6:214-228 and the antibodies described therein. The potency of compounds to act as inhibitors against collagenases can be determined as described by T. Cawston and A. Barrett (1979) Anal. Biochem. 99:340-345.

Inhibition of Metalloproteinase Activity in Cell/Tissue Based Activity:**Test as an agent to inhibit membrane sheddases such as TNF convertase**

The ability of the compounds of this invention to inhibit the cellular processing of TNF α production may be assessed in THP-1 cells using an ELISA to detect released TNF

5 essentially as described K. M. Mohler *et al.*, (1994) Nature 370:218-220. In a similar fashion the processing or shedding of other membrane molecules such as those described in N. M. Hooper *et al.*, (1997) Biochem. J. 321:265-279 may be tested using appropriate cell lines and with suitable antibodies to detect the shed protein.

Test as an agent to inhibit cell based invasion

10 The ability of the compound of this invention to inhibit the migration of cells in an invasion assay may be determined as described in A. Albini *et al.*, (1987) Cancer Research 47:3239-3245.

Test as an agent to inhibit whole blood TNF sheddase activity

The ability of the compounds of this invention to inhibit TNF α production is

15 assessed in a human whole blood assay where LPS is used to stimulate the release of TNF α . Heparinized (10Units/ml) human blood obtained from volunteers is diluted 1:5 with medium (RPMI1640 + bicarbonate, penicillin, streptomycin and glutamine) and incubated (160 μ l) with 20 μ l of test compound (triplicates), in DMSO or appropriate vehicle, for 30 min at 37°C in a humidified (5%CO₂/95%air) incubator, prior to addition of 20 μ l LPS (E. coli. 0111:B4;

20 final concentration 10 μ g/ml). Each assay includes controls of diluted blood incubated with medium alone (6 wells/plate) or a known TNF α inhibitor as standard. The plates are then incubated for 6 hours at 37°C (humidified incubator), centrifuged (2000rpm for 10 min; 4°C), plasma harvested (50-100 μ l) and stored in 96 well plates at -70°C before subsequent analysis for TNF α concentration by ELISA.

25 Test as an agent to inhibit in vitro cartilage degradation

The ability of the compounds of this invention to inhibit the degradation of the aggrecan or collagen components of cartilage can be assessed essentially as described by K. M. Bottomley *et al.*, (1997) Biochem J. 323:483-488.

Pharmacodynamic test

30 To evaluate the clearance properties and bioavailability of the compounds of this invention an ex vivo pharmacodynamic test is employed which utilises the synthetic substrate assays above or alternatively HPLC or Mass spectrometric analysis. This is a generic test

which can be used to estimate the clearance rate of compounds across a range of species. Animals (e.g. rats, marmosets) are dosed iv or po with a soluble formulation of compound (such as 20%w/v DMSO, 60% w/v PEG400) and at subsequent time points (e.g. 5, 15, 30, 60, 120, 240, 480, 720, 1220 mins) the blood samples are taken from an appropriate vessel into 10U heparin. Plasma fractions are obtained following centrifugation and the plasma proteins precipitated with acetonitrile (80%w/v final concentration). After 30 mins at -20°C the plasma proteins are sedimented by centrifugation and the supernatant fraction is evaporated to dryness using a Savant speed vac. The sediment is reconstituted in assay buffer and subsequently analysed for compound content using the synthetic substrate assay. Briefly, a compound concentration-response curve is constructed for the compound undergoing evaluation. Serial dilutions of the reconstituted plasma extracts are assessed for activity and the amount of compound present in the original plasma sample is calculated using the concentration-response curve taking into account the total plasma dilution factor.

In Vivo Assessment

15 Test as an anti-TNF agent

The ability of the compounds of this invention as *ex vivo* TNF α inhibitors is assessed in the rat. Briefly, groups of male [Wistar Alderley Park (AP)] rats (180-210g) are dosed with compound (6 rats) or drug vehicle (10 rats) by the appropriate route e.g. peroral (p.o.), intraperitoneal (i.p.), subcutaneous (s.c.). Ninety minutes later rats are sacrificed using a rising concentration of CO₂ and bled out via the posterior vena cavae into 5 Units of sodium heparin/ml blood. Blood samples are immediately placed on ice and centrifuged at 2000 rpm for 10 min at 4°C and the harvested plasmas frozen at -20°C for subsequent assay of their effect on TNF α production by LPS-stimulated human blood. The rat plasma samples are thawed and 175 μ l of each sample are added to a set format pattern in a 96U well plate. Fifty μ l of heparinized human blood is then added to each well, mixed and the plate is incubated for 30 min at 37°C (humidified incubator). LPS (25 μ l; final concentration 10 μ g/ml) is added to the wells and incubation continued for a further 5.5 hours. Control wells are incubated with 25 μ l of medium alone. Plates are then centrifuged for 10 min at 2000 rpm and 200 μ l of the supernatants are transferred to a 96 well plate and frozen at -20°C for subsequent analysis of TNF concentration by ELISA.

Data analysis by dedicated software calculates for each compound/dose:

$$\text{Percent inhibition of TNF}\alpha = \frac{\text{Mean TNF}\alpha (\text{Controls}) - \text{Mean TNF}\alpha (\text{Treated})}{\text{Mean TNF}\alpha (\text{Controls})} \times 100$$

Test as an anti-arthritic agent

- 5 Activity of a compound as an anti-arthritic is tested in the collagen-induced arthritis (CIA) as defined by D. E. Trentham *et al.*, (1977) J. Exp. Med. 146:857. In this model acid soluble native type II collagen causes polyarthritis in rats when administered in Freund's incomplete adjuvant. Similar conditions can be used to induce arthritis in mice and primates.

Test as an anti-cancer agent

- 10 Activity of a compound as an anti-cancer agent may be assessed essentially as described in I. J. Fidler (1978) Methods in Cancer Research 15:399-439, using for example the B16 cell line (described in B. Hibner *et al.*, Abstract 283 p75 10th NCI-EORTC Symposium, Amsterdam June 16 - 19 1998).

The invention will now be illustrated but not limited by the following Examples:

15


EXAMPLES

Example 1

- Acetic anhydride (1 ml) was added dropwise to formic acid (3 ml) at 0°C and the mixture was stirred at 0°C for 30 minutes. This mixture was added dropwise to a solution of
20 4-(4-fluorophenyl)-1-[2-(1-phenethylcarbonylpiperidin-4-yl)-2-hydroxylaminoethylsulphonyl]-piperazine (0.65 g) in tetrahydrofuran (5 ml) at 0°C and the mixture was allowed to warm to ambient temperature and was stirred for 10 hours. The reaction mixture was evaporated to small volume, aqueous sodium bicarbonate was added and the mixture was extracted with ethyl acetate (2x25 ml).

- 25 The ethyl acetate extracts were dried and evaporated to dryness. The gum so obtained was subjected to chromatography on silica eluted initially with an ethyl acetate:isohexane mixture (3:2 v/v) and then an ethyl acetate:methanol mixture (9:1). There was obtained 4-(4-fluorophenyl)-1-[2-(1-phenethylcarbonylpiperidin-4-yl)-2-{O-formylhydroxylamino}ethylsulphonyl]-piperazine as a gum, yield 230 mg, M+H = 547.

30




A mixture of 4-(4-fluorophenyl)-1-[2-(1-phenethylcarbonylpiperidin-4-yl)-
 5 ethenylsulphonyl]-piperazine (0.75 g) and 50% aqueous hydroxylamine (5 ml) in
 tetrahydrofuran (10 ml) was stirred for 48 hours. The mixture was evaporated to dryness and
 water (20 ml) was added. The mixture was extracted with ethyl acetate (2 x 15 ml) and the
 extracts were washed with water and dried. Removal of the solvent gave 4-(4-fluorophenyl)-
 1-[2-(1-phenethylcarbonylpiperidin-4-yl)-2-hydroxylaminoethylsulphonyl]-piperazine (0.65 g)
 10 as a gum, $M+H = 519$ (518).

3-Phenylpropionyl chloride (0.21 ml) was added dropwise to a solution of 4-(4-
 fluorophenyl)-1-[2-(piperidin-4-yl)-ethenylsulphonyl]-piperazine (0.5 g) in dichloromethane
 containing triethylamine (0.2 ml). The mixture was stirred for 3 hours, evaporated to dryness,
 diluted with water and extracted with ethyl acetate (2 x 15 ml). The ethyl acetate extracts
 15 were combined and washed with aqueous sodium bicarbonate, water and dried. Removal of
 the solvent gave 4-(4-fluorophenyl)-1-[2-(1-phenethylcarbonylpiperidin-4-yl)-
 ethenylsulphonyl]-piperazine as a gum, $M+H = 486$ (485).

A mixture of 4-(4-fluorophenyl)-1-[2-(1-t-butoxycarbonylpiperidin-4-yl)-
 ethenylsulphonyl]-piperazine (1.96 g) and trifluoroacetic acid (5 ml) was stirred at ambient
 20 temperature for 5 hours. The mixture was evaporated to dryness, diluted with water, basified
 with aqueous 2M sodium hydroxide and extracted with ethyl acetate (2 x 20 ml). Removal of
 the solvent gave 4-(4-fluorophenyl)-1-[2-(piperidin-4-yl)-ethenylsulphonyl]-piperazine.

In like manner using 4-(4-fluorophenyl)-1-[2-(1-t-butoxycarbonylpiperidin-4-yl)-2-
 {O-formylhydroxylamino}ethylsulphonyl]-piperazine as starting material there was obtained
 25 4-(4-fluorophenyl)-1-[2-(piperidin-4-yl)-2-{O-formylhydroxylamino}ethylsulphonyl]-
 piperazine, $M+H = 415$.





n-Butyl lithium (8.6 ml of a 1.6 M solution in THF) was added dropwise to a
 5 suspension of 4-(4-fluorophenyl)-1-methanesulphonylpiperazine (3.52 g) in THF (40 ml) at -
 78 °C and the mixture was stirred for 30 minutes. Diethylchlorophosphate (1.97 ml) was
 added dropwise and the mixture was stirred at -78 °C for a further 30 minutes. n-Butyl
 lithium (8.6 ml of a 1.6 M solution in THF) was added dropwise and stirred for 30 minutes. A
 solution of 1-(t-butoxycarbonyl)-piperidine-4-aldehyde (2.91 g) in THF (5 ml) was added
 10 dropwise and the mixture was allowed to warm to ambient temperature and was stirred for 10
 hours. Saturated aqueous ammonium chloride solution (5 ml) was added, the reaction mixture
 was diluted with ethyl acetate (25 ml) and washed with water. Removal of the solvent gave 4-
 (4-fluorophenyl)-1-[2-(1-t-butoxycarbonylpiperidin-4-yl)-ethenylsulphonyl]-piperazine
 as a gum which solidified on standing, M+H = 455 (454).

15

Example 2



In like manner there were prepared compounds of the formula:




R	M+H
-COOBu ^t	515
	583

Example 3


5 Using procedures analogous to those outlined in Example 1 there were prepared:




- 22 -




mpt 204




mpt 116-20




mpt 189



mpt 182



mpt 182




5








mpt 121

Example 4

Using procedures analogous to those outlined in Example 1 there were prepared:

10




R	MPt °C	M+H
		589
		589
		623
		559
		641
		561
CF ₃ CH ₂ SO ₂ -		561
iso-PrSO ₂ -	170-172	
PhCH ₂ NHCO-	130	
	132	
PhCH ₂ CH ₂ NHCO-	124	
iso-PrNHCO-	155-158	



Example 5

Using procedures analogous to those outlined in Example 1 and using the starting material 1-(t-butoxycarbonyl)-3-formylpiperidine [CAS number 118156-93-7] there were prepared:

5




R	MPt °C	M+H
PhCO-		519
n-PrSO ₂ -		521
MeSO ₂ -		493
PhNHCO-		534
PhSO ₂ -		555
		589
		589
	108	
	105	
		561
CF ₃ CH ₂ SO ₂ -	87-90	

iso-PrSO ₂ -		521
PhCH ₂ NHCO-	95-100	
	110	
PhCH ₂ CH ₂ NHCO-	90	
iso-PrNHCO-	95-97	
		559

CLAIMS:

What we claim is:-

- 5 1. A compound of the formula I



wherein ring B is a monocyclic or bicyclic alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl ring comprising up to 12 ring atoms and containing one or more heteroatoms independently chosen from N, O, and S; alternatively ring B may be biphenyl; ring B may optionally be linked to ring A by a C1-4 alkyl or a C1-4 alkoxy chain linking the 2-position of ring B with a carbon atom alpha to X2;

each R3 is independently selected from hydrogen, halogen, NO₂, COOR wherein R is hydrogen or C1-6alkyl, CN, CF₃, C1-6 alkyl, -S-C1-6 alkyl, -SO-C1-6 alkyl, -SO₂-C1-6 alkyl, C1-6 alkoxy and up to C10 aryloxy, n is 1,2 or 3;

P is -(CH₂)_n- wherein n = 0, 1, 2, or P is an alkene or alkyne chain of up to six carbon atoms; where X₂ is C, P may be -Het-, -(CH[R₆])_n-Het-, -Het-(CH[R₆])_n-or -Het-(CH[R₆])_n-Het-, wherein Het is selected from - CO-, -S-, SO-, -SO₂-, -NR₆-, or -O- wherein n is 1 or 2, or P may be selected from -CO-N(R₆)-, -N(R₆)-CO-, -SO₂-N(R₆)- and -N(R₆)-SO₂-, and R₆ is hydrogen, C1-6 alkyl, up to C10 aralkyl or up to C9 heteroalkyl;

Ring A is a 5-7 membered aliphatic ring and may optionally be mono- or di-substituted by optionally substituted C1-6 alkyl or C1-6 alkoxy, each substituent being independently selected from halogen, C1-6 alkyl or an oxo group;

25 X₁ and X₂ are independently selected from N and C, where a ring substituent on ring A is an oxo group this is preferably adjacent a ring nitrogen atom;

Y is selected from -SO₂- and -CO-;

30 Z is -CONHOH, Y is -CO- and Q is selected from -C(R₆)(R₇)-, -C(R₆)(R₇)-CH₂-, -N(R₆)-, and -N(R₆)-CH₂- wherein R₆ is as defined above, and solely in relation to Q as here defined, R₆ may also represent up to C10 aryl and up to C9 heteroaryl, and R₇ is H, C1-6

alkyl, or together with R6 forms a carbocyclic or heterocyclic spiro 5, 6 or 7 membered ring, the latter containing at least one heteroatom selected from N, O, and S;

Z is -CONHOH, Y is -SO₂- and Q is selected from -C(R6)(R7)-, and -C(R6)(R7)-CH₂-;

5 or Z is -N(OH)CHO and Q is selected from -CH(R6)-, -CH(R6)-CH₂-, and -N(R6)-CH₂-;

R1 is H, or C1-6 alkyl;

Z is selected from -COOH, -CONHOH, -N(OH)CHO and N(OH)COR wherein R is C1-6alkyl, up to C10 aryl and up to C9 aralkyl

10 and R2 is a heterocyclalkyl ring having 5-7 ring atoms and comprising one or two ring heteroatoms independently selected from oxygen, nitrogen and sulphur, the ring being optionally substituted by (i) Y-R9 wherein R9 is C1-6 alkyl, up to C10 aryl, up to C12 aralkyl or up to C12 heteroaryl(hetero)alkyl, or (ii) Y-T-R9 wherein Y and R9 are as previously defined and T is oxygen or N-R8 wherein R8 is hydrogen or C1-6 alkyl, the heteroatom(s)
15 being independently selected from oxygen, nitrogen and sulphur; R9 and R8 independently being optionally substituted by one or two groups selected from halogen, NO₂, CN, CF₃, C1-6 alkyl, -S-C1-6 alkyl, -SO-C1-6 alkyl, -SO₂-C1-6 alkyl and C1-6 alkoxy;

or a pharmaceutically-acceptable salt or in vivo hydrolysable precursor thereof.

20 2. A compound as claimed in claim 1 and wherein:

ring A is a 5-6 membered aliphatic ring and is optionally mono- or di-substituted by optionally substituted C1-6 alkyl or C1-6 alkoxy, each substituent being independently selected from halogen, C1-6 alkyl or an oxo group;

R3 is hydrogen, halogen, NO₂, CF₃, C1-4 alkyl, and C1-4 alkoxy;

25 n is 1 or 2;

ring B is monocyclic or bicyclic cycloalkyl, aryl, aralkyl or heteroaryl having up to 10 ring atoms;

P is -(CH₂)_n- wherein n is 0 or 1, or P is -NH-CO-;

one or both of X₂ and X₁ = N;

30 Y is -SO₂- or -CO-;

Q is -CH(R6)-, -CH(R6)-CH₂-, -N(R6)-, and -N(R6)-CH₂- wherein R6 is hydrogen or C1-6 alkyl; when Q = -N(R6)-, or -N(R6)-CH₂- then Y may also be -CS-, also Q may be linked to R1 or R2 to form a 5-7 alkyl or heteroalkyl ring;

R1 = hydrogen, or C1-4 alkyl.

Z = -CONHOH- or -N(OH)CHO

and R2 is a heterocyclylalkyl ring having 5-7 ring atoms and comprising one or two ring heteroatoms independently selected from oxygen, nitrogen and sulphur, the ring being
5 optionally substituted by (i) Y-R9 wherein R9 is C1-6 alkyl, up to C10 aryl, up to C12 aralkyl or up to C12 heteroaryl(hetero)alkyl, or (ii) Y-T-R9 wherein Y and R9 are as stated in claim 1 and T is oxygen or N-R8 wherein R8 is hydrogen or C1-6alkyl, the heteroatom(s) being independently selected from oxygen, nitrogen and sulphur; R9 and R8 independently being optionally substituted by one or two groups selected from halogen, NO2, CN, CF3, C1-6
10 alkyl, -S-C1-6 alkyl, -SO-C1-6 alkyl, -SO2-C1-6 alkyl and C1-6 alkoxy;
or a pharmaceutically-acceptable salt or in vivo hydrolysable precursor thereof.

3. A compound as claimed in claim 1 and wherein:

R3 is hydrogen, chlorine, fluorine, NO2, CF3, methyl, ethyl, methoxy, ethoxy;
15 ring B is phenyl, biphenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl;
P is a direct bond;
both X2 and X1 are N;
Y is -SO2-;
Q is -CH2-;

20 R2 is a heterocyclylalkyl ring having 5-7 ring atoms and comprising one or two ring heteroatoms independently selected from oxygen, nitrogen and sulphur, the ring being optionally substituted by (i) Y-R9 wherein Y is as stated in claim 1 and R9 is C1-6 alkyl or alkylamino, up to C10 aryl or arylamino, up to C12 aralkyl or aralkylamino, up to C12 heteroaryl(hetero)alkyl, R9 independently being optionally substituted by one or two groups
25 selected from halogen, NO2, CN, CF3, C1-6 alkyl, -S-C1-6 alkyl, -SO-C1-6 alkyl, -SO2-C1-6 alkyl and C1-6 alkoxy;

R1 is hydrogen;

Z is -N(OH)CHO;

or a pharmaceutically-acceptable salt or in vivo hydrolysable precursor thereof.

30

4. A compound as claimed in claim 1 and wherein:

R3 is methoxy, fluorine or 4-fluoro;

ring A is unsubstituted;

ring B is phenyl, pyridyl, or 2-pyridyl;

R2 is optionally substituted 3-piperidinyl, 4-piperidinyl or N-substituted 4-piperidinyl, wherein the substituents are as stated in claim 3;

5 or a pharmaceutically-acceptable salt or in vivo hydrolysable precursor thereof.

5. A compound as claimed in claim 1 and wherein R2 is 3- or 4-piperidinyl, optionally N-substituted by Y-R9 wherein Y is as stated in claim 1 and R9 is C1-4 alkyl or alkylamino, C6 aryl or arylamino, up to C10 aralkyl or aralkylamino or up to C10 heteroaryl(hetero)alkyl, 10 R9 independently being optionally substituted by one or two groups selected from halogen, CF3, and C1-4 alkyl;

or a pharmaceutically-acceptable salt or in vivo hydrolysable precursor thereof.

6. A pharmaceutical composition which comprises a compound of the formula (I) as 15 claimed in claim 1 or a pharmaceutically acceptable salt or an in vivo hydrolysable ester and a pharmaceutically acceptable carrier.

7. A compound of the formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof for use in a method of therapeutic treatment of the 20 human or animal body.



8. A method of treating a metalloproteinase mediated disease condition which comprises administering to a warm-blooded animal a therapeutically effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.

25 9. A process for preparing a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof which process comprises

a) reacting a compound of the formula (II) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof with a compound of the formula (III)

30

- 31 -




wherein X_1^1 represents X or a precursor of X (whether by modification or displacement) or an activated form of X suitable for reaction with Y_1 ;

- 5 Y_1 represents Y, a precursor of Y, or an activated form of Y suitable for reaction with X_1^1 ;

by way of non-limiting example, when X is C then X_1 may be derivatised to include a precursor of Y for reaction with a compound of formula III wherein Y^1 is a precursor of Y;

- 10 Z^1 represents a protected form of Z, a precursor of Z (whether by modification or displacement of Z^1) or an activated form of Z;
- or

b) reacting a compound of the formula (IV) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof with a compound of the formula (V).




wherein B^I represents a suitable ring function or substituent group for reaction with P^I ; Z^I is as hereinbefore defined; and

- 5 P^I represents a suitably activated form of the linker P for reaction with A^I ;

or

c) reacting a compound of the general formula (VIII)






- 10 wherein $R2^*$ is a precursor for R2 with appropriate reagent(s) in one or more steps to yield R2. The group Z is conveniently protected during such steps. By way of non-limiting example $R2^*$ is a piperidine or piperazine ring;

or

(d) reacting a compound of the formula IX with an appropriate compound of the formula R1-

- 15 CO-R2 to yield an alkene of the formula X, which is then converted to a compound of the formula XI wherein Z^* is a hydroxylamine precursor of the group Z, and then converting Z^* to the group Z, all as set out below:



10. The use of a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable precursor thereof in the preparation of a medicament for use in a disease condition mediated by one or more metalloproteinase enzymes.

11. The use of a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable precursor thereof in the preparation of a medicament for use in the treatment of arthritis.

12. The use of a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable precursor thereof in the preparation of a medicament for use in the treatment of atherosclerosis.

INTERNATIONAL SEARCH REPORT

Inte. onal Application No

PCT/GB 00/02085

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D211/28 C07D401/12 C07D409/12 A61K31/445 A61K31/4535
A61P19/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 02510 A (BISSOLINO PIERLUIGI ; JABES DANIELA (IT); ALPEGIANI MARCO (IT); PER) 21 January 1999 (1999-01-21) claim 1; examples	1-12
A	US 5 817 822 A (MACPHERSON LAWRENCE J ET AL) 6 October 1998 (1998-10-06) claim 1	1-12
A	DE 198 02 350 A (HOFFMANN LA ROCHE ; AGOURON PHARMA (US)) 30 July 1998 (1998-07-30) claim 1; examples	1-12
A	WO 99 18074 A (DU PONT PHARM CO) 15 April 1999 (1999-04-15) claim 1; examples	1-12
	--- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

13 November 2000

Date of mailing of the international search report

24/11/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

De Jong, B

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/02085

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 00 12478 A (ZENECA PHARMA SA ;TUCKER HOWARD (GB); WATERSON DAVID (GB); ZENECA) 9 March 2000 (2000-03-09) compound in which R1 is N-PhCH2-4-piperidiny1 page 42	1-12
P,X	WO 99 38843 A (DARWIN DISCOVERY LTD) 5 August 1999 (1999-08-05) claims; examples	1,6-8, 10-12

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1,4-12 (all partially)

Present claims 1,4-12 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds of formula I, in which Z is -CONHOH, -N(OH)CHO or -N(OH)COR.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/02085

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9902510 A	21-01-1999	AU 8858398 A EP 0925289 A	08-02-1999 30-06-1999
US 5817822 A	06-10-1998	US 5646167 A US 5552419 A US 5506242 A AU 6124996 A WO 9640101 A US 5672615 A AT 196762 T AU 692553 B AU 2536995 A CA 2192092 A DE 69519024 D EP 0766672 A FI 965156 A HU 76548 A WO 9600214 A JP 11505502 T NO 965568 A ZA 9505206 A	08-07-1997 03-09-1996 09-04-1996 30-12-1996 19-12-1996 30-09-1997 15-10-2000 11-06-1998 19-01-1996 04-01-1996 09-11-2000 09-04-1997 20-12-1996 29-09-1997 04-01-1996 21-05-1999 17-02-1997 27-12-1995
DE 19802350 A	30-07-1998	AU 6614098 A BG 103586 A BR 9807508 A CN 1250445 T WO 9832748 A EP 0958287 A ES 2136037 A FR 2758559 A GB 2321641 A HR 980036 A IT MI980091 A NO 993587 A PL 334846 A US 5998412 A ZA 9800376 A US 6130220 A	18-08-1998 31-03-2000 21-03-2000 12-04-2000 30-07-1998 24-11-1999 01-11-1999 24-07-1998 05-08-1998 31-12-1998 23-07-1998 22-09-1999 27-03-2000 07-12-1999 23-07-1998 10-10-2000
WO 9918074 A	15-04-1999	AU 9686698 A EP 1027332 A HR 980533 A NO 20000783 A US 6057336 A	27-04-1999 16-08-2000 31-10-1999 29-05-2000 02-05-2000
WO 0012478 A	09-03-2000	AU 5524799 A	21-03-2000
WO 9938843 A	05-08-1999	AU 2291499 A NO 20003868 A	16-08-1999 28-07-2000